Yejin Kim, Postdoctoral Scholar at the University of Washington, shared a post on LinkedIn:
“Our invited review on cardiac radiosensitivity is now live in The Lancet Oncology!
I am thrilled to announce the publication of our invited scoping review, “Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy,” in the March 2026 issue of The Lancet Oncology.
As concurrent chemoradiotherapy followed by ICI consolidation becomes the standard of care for unresectable stage III NSCLC, understanding the evolving cardiac risk profile is more critical than ever. In this review, we address six key questions regarding the convergence of cardiotoxicity from both radiation and immunotherapy, highlighting the need for long-term studies to balance oncological efficacy with cardiovascular safety.
A huge thank you to my esteemed co-authors for their collaboration and insights:
James Bates, MD
Hong In Yoon, MD PhD
Clemens Grassberger, PhD
It has been a privilege to lead this work and contribute to the discussion on balancing oncological efficacy with cardiovascular safety.
Special Access: Thanks to Elsevier, we have a personalized share link that provides 50 days of free access (no registration required) until April 21, 2026.
Read the full paper here.”
Article: Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review
Authors: Yejin Kim, James Edward Bates, Hong In Yoon, Clemens Grassberger.
Other articles on OncoDaily.